Gilead Sciences (GILD) is a biotechnology company in the Health Care sector. Listed on the NASDAQ, Gilead Sciences is a component of the S&P 500 index. As of 2026-06-10, the stock is trading at $121.48.
Key Metrics & Risk
Based on 5-year historical data from Yahoo Finance (daily returns, annualized using 252 trading days).
| Metric | Value |
|---|---|
| Latest Price | $121.48 |
| Latest Date | 2026-06-10 |
| Expected Return (Annualized) | 18.06% |
| Risk / Std Dev (Annualized) | 24.09% |
| Sharpe Ratio (rf=4.5%) | 0.56 |
S&P 500 Context
- Sector: Health Care
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Index: S&P 500 Component
Risk/Return Profile
The stock shows an annualized expected return of 18.06% with an annualized volatility of 24.09%. The Sharpe ratio of 0.56 (assuming 4.5% risk-free rate) indicates moderate risk-adjusted returns relative to the risk-free rate.
Modern Portfolio Theory Positioning
This stock is plotted on the S&P 500 Modern Portfolio Theory chart which visualizes the risk/return trade-off across all S&P 500 components. The chart uses Sharpe ratio as the color dimension, allowing quick identification of stocks with superior risk-adjusted performance.
Fundamentals
| Metric | Value |
|---|---|
| Market Cap | 150.83B |
| Enterprise Value | 163.1B |
| Trailing P/E | 16.53 |
| Forward P/E | 12.66 |
| Price to Book | 6.42 |
| Price to Sales | 5.07 |
| EV/Revenue | 5.49 |
| EV/EBITDA | 11.07 |
| Profitability | | | Profit Margin | 30.99% | | Operating Margin | 39.28% | | ROE | 43.36% | | ROA | 13.29% |
| Growth | | | Revenue Growth | 4.4% | | Earnings Growth | 54.8% |
| Dividend | | | Dividend Yield | 270.0% | | Payout Ratio | 43.4% | | 5Y Avg Yield | 362.0% |
| Financial Health | | | Total Revenue | 29.74B | | Total Debt | 22.17B | | Total Cash | 9.82B | | Free Cash Flow | 7.93B | | Operating Cash Flow | 10.81B |
| Price & Technical | | | 52W High | $157.29$ | | 52W Low | $104.46$ | | 50-Day Avg | $133.83$ | | 200-Day Avg | $129.01$ | | Beta | 0.33 | | Shares Outstanding | 1.24B | | Float Shares | 1.24B | | Insider Holdings | 0.12% | | Institutional Holdings | 92.22% | | Short Ratio | 3.92 | | Short % of Float | 2.07% |
| Analyst Targets | | | Target High | $180.0$ | | Target Low | $122.0$ | | Target Mean | $157.83$ | | Target Median | $160.0$ | | # of Analysts | 29 | | Recommendation | buy |
Disclaimer
This analysis is for educational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Always conduct your own research or consult a qualified financial advisor before making investment decisions.